{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"MDASI questionnaire completed on days 8, 15, and 22 after enrollment. The 'primary success' is defined as a 3-point reduction in pain score on the MDASI. Scores from baseline and from four weeks later compared using the MDASI average pain intensity on a scale of 0 (no pain) to 10 (worst pain).","groups":[{"description":"Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.","id":"OG000","title":"Arm I: Opioid Rotation to Oral Methadone"},{"description":"Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.","id":"OG001","title":"Arm II: Opioid Rotation to Another Long-acting Strong Opioid"}],"populationDescription":"No Analysis accomplished as there is not sufficient participant data to meet the study end points.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Number of Participants With at Least a 3-point Reduction in Pain Score on the M.D. Anderson Symptom Inventory (MDASI)","type":"PRIMARY"}